Navigation Links
Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Date:2/10/2011

company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world.  Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas.  Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide.  The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in approximately 100 countries.
More information on Cephalon and its products is available at http://www.cephalon.com

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance for first-quarter 2011 and full-year 2011 and SG&A and R&D guidance for the first-quarter 2011 and full-year 2011; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013  In a letter to ... , M.D., of Lake View, Iowa , ... receive annual influenza vaccine is neither scientifically justified nor ethically ... article in the summer issue of the Journal ... official statistics are correct, and an average of 36,000 patients ...
(Date:6/18/2013)... , June 18, 2013 The board ... LLY ) has declared a dividend for the ... outstanding common stock. The dividend is ... the close of business on August 15, 2013. ... growing portfolio of pharmaceutical products by applying the latest ...
(Date:6/18/2013)... DENVER , June 18, 2013  Healthgrades, ... evaluate, compare and connect with physicians and hospitals, ... 2013: "Lean in" When Making Healthcare Decisions to ... the best performing hospitals for maternity care, gynecologic ... the treatment of women across 15 of the ...
Breaking Medicine Technology:Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4
... Reportlinker.com announces that a new market research ... The Global Pharmaceutical Fine Chemicals ... http://www.reportlinker.com/p0535967/The-Global-Pharmaceutical-Fine-Chemicals-Market-Outlook-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Chemical_and_Material Introduction ... comprehensive overview of the global pharmaceutical fine ...
... SAN DIEGO, Oct. 18, 2011 Halozyme Therapeutics, ... company developing and commercializing products targeting the ... and drug delivery markets, today announced that the ... that women with HER2-positive early breast cancer who ...
Cached Medicine Technology:The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 2The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 3The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 4The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 5Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 2Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 3Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 4
(Date:6/18/2013)... Lauren Sciences, a privately-held biotechnology company furthering development ... today that it was independently recognized as a ... Platform, and selected as a Featured Company, in ... , The report, " Early Stage Drug Delivery ... features companies MCD Group independently selected as technology ...
(Date:6/18/2013)... Case Medical Center enrolled their first patients in the ... novel, less-invasive procedure to help clear blockages in carotid ... than 300,000 people in the United States are diagnosed ... left untreated, these blockages can slow or even stop ... stroke, also known as a "brain attack." , ...
(Date:6/18/2013)... scrambling to gather data for the FDA to support ... injury in the United States. The University of Rochester ... the Journal of Neurotrauma that it might ... of one., Jeffrey J. Bazarian, M.D., M.P.H., an associate ... first to show that measuring a combination of two ...
(Date:6/18/2013)... first computer guided fitness training system using a ... three winners of the LeWeb,13 London Startup Competition, ... The startup company, Genetrainer, building on University of ... Ralph Pethica and Julian Gough, Professor of Bioinformatics ... selected from over 350 startups to be one ...
(Date:6/18/2013)... York, Pennsylvania (PRWEB) June 18, 2013 Two ... which unfurled in Philadelphia, Pennsylvania. As reported by ... dead in Philadelphia building collapse, 13 injured," a building scheduled ... in a nearby shop, and six of those persons succumbed ... the state and the country. , The situation should serve ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2Health News:Ensuring The Safety of Pennsylvania Worksites 2Health News:Ensuring The Safety of Pennsylvania Worksites 3
... due to the combination of just two genes, according to a ... the Journal of Clinical Endocrinology and Metabolism this week,// identifies one ... contributors to height in men. These genes may also help explain ... tall version of both of these genes you will be taller ...
... ribozyme, an enzyme that can be used to kill the deadly ... had been designed using the viral clones and would kill the ... efficacy of the ribozyme was being tested on animals. The cloned ... presence of Hepatitis E virus. , , ...
... fruits and vegetables, but don't forget whole grains, if ... disease and cancer, researchers say.// Fruits and vegetables especially ... risk by about 32%. , According to a study ... of two to three slices of whole-grain bread each day were ...
... Hopkins University have found that treadmill testing is a ... problems. Many people who develop// heart disease have no ... researchers, treadmill testing can show up hidden weaknesses long ... a study of nearly 2,000 men and 3,000 women ...
... research involves a drug called zoledronic acid, which is approved ... which calcium seeps from the bones. The drug was found ... density, and the effect persisted for at least a year ... blood.// ,It will be about five years before doctors ...
... new recommendations telling pediatricians to screen all children for ... serious illness. Children who snore loudly may// suffer from ... can lead to growth, heart and pulmonary problems. ... older than age 1, the pediatricians' group urges doctors ...
Cached Medicine News:
Lumicon 48 mm red filter....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
... child-friendly vision test that's ... just seconds. Welch Allyn ... objective, accurate vision test ... detection of refractive error, ...
... Classic is a black and ... use by people who have ... picture control selector, the Classic ... high-contrast black text on a ...
Medicine Products: